Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: An updated comprehensive review and meta-analysis

PACE - Pacing and Clinical Electrophysiology

Volumn 36, Issue 1, 2013, Pages 122-133

  Chatterjee, Saurav ^a   Sardar, Partha ^b   Lichstein, Edgar ^c   Mukherjee, Debabrata ^d   Aikat, Shamik ^e  

^a BROWN UNIVERSITY   (United States)

^b METROPOLITAN HOSPITAL CENTER   (United States)

^c MAIMONIDES MEDICAL CENTER   (United States)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

Author keywords

atrial fibrillation; rate control; rhythm control

Indexed keywords

AMIODARONE; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; MORACIZINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL;

BLEEDING; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART RATE; HOSPITAL READMISSION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SINUS RHYTHM; SYSTEMATIC REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DEFIBRILLATORS, IMPLANTABLE; EVIDENCE-BASED MEDICINE; HUMANS; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84872176957     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2012.03513.x     Document Type: Review

References (31)

1. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, et al.; The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
2. de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA,. Rate vs rhythm control in patients with atrial fibrillation: A meta-analysis. Arch Intern Med 2005; 165: 258-262.
3. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, Achremczyk P,; Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: The results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004; 126: 476-486.
4. Hohnloser SH, Kuck K-H, Lilienthal J,. Rhythm or rate control in atrial fibrillation-pharmacologic intervention in atrial fibrillation (PIAF): A randomized trial. Lancet 2000; 356: 1789-1794.
5. Crijns HJ,. Rate versus rhythm control in patients with atrial fibrillation: What the trials really say. Drugs 2005; 65: 1651-1667.
6. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, et al.; American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: e269-367.
7. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, et al.; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667-2677.
8. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, et al.; STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41: 1690-1696.
9. Ogawa S, Yamashita T, Yamazaki T, Aizawa Y, Atarashi H, Inoue H, Ohe T, et al.; J-RHYTHM Investigators. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 2009; 73: 242-248. Epub 2008 Dec 8.
10. Testa L, Biondi-Zoccai GG, Dello Russo A, Bellocci F, Andreotti F, Crea F,. Rate-control vs. rhythm-control in patients with atrial fibrillation: A meta-analysis. Eur Heart J 2005; 26: 2000-2006.
11. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003; 107: 2920-2925.
12. Chinushi M, Iijima K,. Rate control is a better initial treatment for patients with atrial fibrillation and heart failure-rhythm control vs. rate control: Which is better in the management of atrial fibrillation? (Rate-side). Circ J 2011; 75: 970-378.
13. Chen S, Dong Y, Fan J, Yin Y,. Rate vs. rhythm control in patients with atrial fibrillation-An updated meta-analysis of 10 randomized controlled trials. Int J Cardiol 2011; 153: 96-98.
14. Kong MH, Shaw LK, O'Connor C, Califf RM, Blazing MA, Al-Khatib SM,. Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure? Ann Noninvasive Electrocardiol 2010; 15: 209-217.
15. Sherman DG, Kim SG, Boop BS, Corley SD, Dimarco JP, Hart RG, Haywood LJ, et al.; National Heart, Lung, and Blood Institute AFFIRM Investigators. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med 2005; 165: 1185-1191.
16. Andersen LV, Vestergaard P, Deichgraeber P, Lindholt JS, Mortensen LS, Frost L,. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: A meta-analysis. Heart 2008; 94: 1607-1613.
17. Rienstra M, Van Veldhuisen DJ, Crijns HJ, Van Gelder IC,; RACE Investigator. Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: Data of the RACE study. Eur Heart J 2007; 28: 741-751.
18. Taylor CJ, Hodgkinson J, Hobbs FD,. Rhythm control agents and adverse events in patients with atrial fibrillation. Int J Clin Pract 2010; 64: 1069-1075.
19. Joglar JA, Acusta AP, Shusterman NH, Ramaswamy K, Kowal RC, Barbera SJ, Hamdan MH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: Retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001; 142: 498-501.
20. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, et al.; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010; 376: 875-885.
21. Crandall MA, Horne BD, Day JD, Anderson JL, Muhlestein JB, Crandall BG, Weiss JP, et al. Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors. Pacing Clin Electrophysiol 2009; 32: 981-986.
22. de Silva R, Fox KM,. Angina: Ivabradine for treatment of stable angina pectoris. Nat Rev Cardiol 2009; 6: 329-330.
23. Jons C, Jacobsen UG, Joergensen RM, Olsen NT, Dixen U, Johannessen A, Huikuri H, et al.; Cardiac Arrhythmias and Risk Stratification after Acute Myocardial Infarction (CARISMA) Study Group. The incidence and prognostic significance of new-onset atrial fibrillation in patients with acute myocardial infarction and left ventricular systolic dysfunction: A CARISMA substudy. Heart Rhythm 2011; 8: 342-348.
24. Caldeira D, David C, Sampaio C,. Rate vs rhythm control in patients with atrial fibrillation and heart failure: A systematic review and meta-analysis of randomised controlled trials. Eur J Intern Med 2011; 22: 448-455.
25. Pietrasik A, Kosior DA, Niewada M, Olsen NT, Dixen U, Johannessen A, Huikuri H, et al. The cost comparison of rhythm and rate control strategies in persistent atrial fibrillation. Int J Cardiol 2007; 118: 21-27.
26. Cordina J, Mead G,. Pharmacological cardioversion for atrial fibrillation and flutter. Cochrane Database Syst Rev 2005; 2: CD003713.
27. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med 2009; 6: e1000100.
28. Vora A, Karnad D, Goyal V, Naik A, Gupta A, Lokhandwala Y, Kulkarni H, et al. Control of heart rate versus rhythm in rheumatic atrial fibrillation: A randomized study. J Cardiovasc Pharmacol Ther 2004; 9: 65-73.
29. Okçün B, Yigit Z, Arat A, Küçükoglu SM,. Comparison of rate and rhythm control in patients with atrial fibrillation and nonischemic heart failure. Jpn Heart J 2004; 45: 591-601.
30. Yildiz A, Yigit Z, Okcun B, Baskurt M, Ortak K, Kaya A, Kucukoglu S,. Comparison of rate and rhythm control in hypertension patients with atrial fibrillation. Circ J 2008; 72: 705-708.
31. Camm AJ, Breithardt G, Crijns H, Dorian P, Kowey P, Le Heuzey JY, Merioua I, et al. Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol 2011; 58: 493-501.